CD4 and malignant colon neoplasm: Our results clearly demonstrated that low-dose CTX selectively suppressed the number of IL-10- and TGF-β1-positive cells, increased the number of conventional CD4+ and CD8+ T cells in the spleen, and efficiently inhibited liver metastasis of murine CT26 colon-cancer cells.